About Viela Bio
Viela Bio is a company based in Gaithersburg (United States) founded in 2017 was acquired by Horizon Therapeutics in December 2020.. Viela Bio has raised $357.25 million across 2 funding rounds from investors including Goldman Sachs, Astrazeneca and Horizon Therapeutics. The company has 170 employees as of December 31, 2022. Viela Bio operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others.
- Headquarter Gaithersburg, United States
- Employees 170 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Viela Bio, Inc.
-
Annual Revenue
$11.65 M-77as on Dec 31, 2020
-
Net Profit
$-150.67 M-74as on Dec 31, 2020
-
EBITDA
$-153.88 M-72as on Dec 31, 2020
-
Total Equity Funding
$357.25 M (USD)
in 2 rounds
-
Latest Funding Round
$75 M (USD), Series B
Jun 17, 2019
-
Investors
Goldman Sachs
& 11 more
-
Employee Count
170
as on Dec 31, 2022
-
Acquired by
Horizon Therapeutics
(Dec 31, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Software Development Team
208 people
Leadership Team
193 people
Sales and Marketing
82 people
Data Analysis and Operations Team
73 people
Senior Team
66 people
Operations Team
64 people
Product Management Team
55 people
Scientific Team
34 people
Unlock access to complete
Funding Insights of Viela Bio
Viela Bio has successfully raised a total of $357.25M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $75 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $75.0M
-
First Round
First Round
(28 Feb 2018)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2019 | Amount | Series B - Viela Bio | Valuation | HBM Healthcare Investments | |
| Feb, 2018 | Amount | Series A - Viela Bio | Valuation | 6 Dimensions Capital , Boyu Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Viela Bio
Viela Bio has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Goldman Sachs, Astrazeneca and Horizon Therapeutics. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private investment firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Private equity investments in China are managed by TMCP.
|
Founded Year | Domain | Location | |
|
Investment banking services are delivered across multiple financial sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Viela Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Viela Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Viela Bio Comparisons
Competitors of Viela Bio
Viela Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Viela Bio
Frequently Asked Questions about Viela Bio
When was Viela Bio founded?
Viela Bio was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is Viela Bio located?
Viela Bio is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Is Viela Bio a funded company?
Viela Bio is a funded company, having raised a total of $357.25M across 2 funding rounds to date. The company's 1st funding round was a Series A of $282.25M, raised on Feb 28, 2018.
How many employees does Viela Bio have?
As of Dec 31, 2022, the latest employee count at Viela Bio is 170.
What is the annual revenue of Viela Bio?
Annual revenue of Viela Bio is $11.65M as on Dec 31, 2020.
What does Viela Bio do?
Developer of biologics for treating severe inflammation and autoimmune diseases. Their lead candidate inebilizumab, which is indicated for Neuromyelitis Optica Spectrum Disorder. Other candidates include HZN-825 for diffuse cutaneous systemic sclerosis, HZN-4920 for Sjögrens syndrome, rheumatoid arthritis, kidney transplant, and others. It is a humanized monoclonal antibody that binds and depletes CD19 B cells including plasmablasts and plasma cells.
Who are the top competitors of Viela Bio?
Viela Bio's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Who are Viela Bio's investors?
Viela Bio has 12 investors. Key investors include Goldman Sachs, Astrazeneca, Horizon Therapeutics, Temasek, and HBM Healthcare Investments.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.